GL1X · GenesisL1 explorer

MolNFT v1 · #102219 · protein

Crystal structure of human BRCA1 brct in complex with nonphosphopeptide inhibitor

4OFB · Breast cancer type 1 susceptibility protein: “Crystal structure of human BRCA1 brct in complex with nonphosphopeptide inhibitor”. X-ray diffraction, 2 ligands (ACE, NH2), 2 pockets (best druggability 0.43). MolNFT v1 #102219 on…

PDB
4OFB
Type
protein
Length
221 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Breast cancer type 1 susceptibility protein; Nonphosphopeptide inhibitor
UniProt
P38398
Ligands
ACE, NH2
Pockets
2 · best druggability 0.43

Structure

x-ray diffraction · 2 distinct chains · 33% helix, 18% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ABreast cancer type 1 susceptibility proteinprotein20935% helix, 19% strandP38398
BNonphosphopeptide inhibitorprotein120% helix, 0% strand—

Ligands and binding sites

  • ACE · Acetyl group · ligand · chains B
  • NH2 · Amino group · ion · chains B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 0 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11040.430.7818empty
2620.350.7816empty

Interfaces

1 interface between chains.

  • A–B · 736 Ų buried · 10 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 2 modified, 1 covalent (nonstandard, covalent ligand).

Compared structures

  • 4OFB · Crystal structure of human BRCA1 BRCT in complex with nonphosphopeptide inhibitor · the same entry in another collection · chain A against A, TM-score 1.00
  • P38398 · AlphaFold monomer V2.0 prediction for breast cancer type 1 susceptibility protein (P38398) · a predicted model of the same protein · chain A against A, TM-score 0.99

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.